ONCAlert | Upfront Therapy for mRCC

HCC VIEW MORE >>

The standard of care for some patients with intermediate-stage hepa­tocellular carcinoma may include lenvatinib if investigators further explore results from a proof-of-concept obser­vational study. The recommended treatment for intermediate-stage HCC, transarterial chemo­embolization, is unsuitable in patients with high-tumor-burden HCC, leaving a signif­icant unmet need in clinical practice for this patient subgroup.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.